Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of MK-0457 in advanced solid tumors
NCT02532868Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- May 2005
- Primary completion
- Jan 2008
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of tozasertib in solid tumor, sponsored by Merck & Co. Primary endpoint: Number of Participants Experiencing Dose-Limiting Toxicities at 21 days. Started May 2005; status: terminated.
02
Drugs
tozasertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02532868.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02532868.